实用临床医药杂志2012，Vol.16Issue(19)：91-93,3.
培美曲塞联合顺铂一线治疗晚期肺癌临床观察
Clinical observation of pemetrexed combined with cisplatin in the treatment of advanced lung cancer
摘要
Abstract
Objective To evaluate the efficacy and adverse reactions of pemetrexed combined with cisplatin in patients with advanced lung cancer. Methods Forty-eight patients with advanced lung cancer were randomly divided into two groups. The observation group {n = 24) received pemetrexed combined with cisplatin, and the control group (n = 24) received docetaxel. The efficacy and adverse reactions were evaluated after two cycles. Results The overall response and clinical benefit rate in the observation group were higher than that in the control group, but there was no significant difference. The body mass and KPS scoring in the observation group after treatment were obviously higher, and they were obviously higher than that in the control group. The levels of CA125 and CEA significantly decreased in both groups after treatment, while the observation group showed significantly lower levels than the control group. The incidence of blood toxicity, gastrointestinal reaction and alopecia in the observation group were obviously lower than that in the control group. Conclusion Pemetrexed in combination with cisplatin for advanced lung cancer patients can significantly improve the quality of life, decrease incidence of adverse reactions. It is worthy of clinical application.关键词
培美曲塞/顺铂/肺癌Key words
pemetrexed/ cisplatin/ lung cancer分类
医药卫生引用本文复制引用
杜开颐..培美曲塞联合顺铂一线治疗晚期肺癌临床观察[J].实用临床医药杂志,2012,16(19):91-93,3.基金项目
中国高校医学期刊临床专项资金(11220172) （11220172）
